THLD soars, C sells, ISPH stumbles

Threshold Pharmaceuticals Inc. (Nasdaq: THLD) started 2011 higher 34.08 percent in price Monday to $1.81. Volume of 49,432 shares closed in on its all-day average of 94,631. THLD, based in Redwood City, Calif., Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors.

Citigroup Inc. (NYSE: C) did a brisk business the first Monday after New Year, trading in 43,054,072 shares, making up ground on its daily average of 538,216,000. Prices for the stock pushed ahead 1.8 percent to $4.82, on announcing that on New Year’s Eve, C it had completed transactions with Discover Financial Services and SLM Corporation that resulted in the divestiture of its student loan business, The Student Loan Corporation.

Inspire Pharmaceuticals Inc. (Nasdaq: ISPH) listed downward Monday, losing 58.45 percent in price to $3.49, on volume of 6,848,880 shares, dwarfing a full-day average of 577,058. ISPH announced today the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis.

Tags: C, Financial Stocks, healthcare, ISPH, nasdaq, NYSE, pharmaceutical stocks, THLD

This entry was posted on Monday, January 3rd, 2011 at 11:53 am by Glenn and is filed under Financial Stocks, Health Care Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.